Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 594 entries
Sorted by: Best Match Show Resources per page
Tofacitinib is not a biologic.

Annals of gastroenterology

Marren AS.
PMID: 28042254
Ann Gastroenterol. 2017;30(1):134. doi: 10.20524/aog.2016.0094. Epub 2016 Oct 07.

No abstract available.

Cite
Marren AS. Tofacitinib is not a biologic. Ann Gastroenterol. 2016;30(1):134doi: 10.20524/aog.2016.0094.
Marren, A. S. (2017). Tofacitinib is not a biologic. Annals of gastroenterology, 30(1), 134. https://doi.org/10.20524/aog.2016.0094
Marren, Amy S. "Tofacitinib is not a biologic." Annals of gastroenterology vol. 30,1 (2017): 134. doi: https://doi.org/10.20524/aog.2016.0094
Marren AS. Tofacitinib is not a biologic. Ann Gastroenterol. 2017;30(1):134. doi: 10.20524/aog.2016.0094. Epub 2016 Oct 07. PMID: 28042254; PMCID: PMC5198242.
Copy Download .nbib Format: NLM
Pharmacoeconomic Analysis Tofacitinib Use in Rheumatoid Arthritis Treatment Scheme.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Kulikov A, Komarov I, Zinchuk I.
PMID: 27200847
Value Health. 2014 Nov;17(7):A381. doi: 10.1016/j.jval.2014.08.2621. Epub 2014 Oct 26.

No abstract available.

Cite
Kulikov A, Komarov I, Zinchuk I. Pharmacoeconomic Analysis Tofacitinib Use in Rheumatoid Arthritis Treatment Scheme. Value Health. 2014;17(7):A381doi: 10.1016/j.jval.2014.08.2621.
Kulikov, A., Komarov, I., & Zinchuk, I. (2014). Pharmacoeconomic Analysis Tofacitinib Use in Rheumatoid Arthritis Treatment Scheme. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A381. https://doi.org/10.1016/j.jval.2014.08.2621
Kulikov, A, et al. "Pharmacoeconomic Analysis Tofacitinib Use in Rheumatoid Arthritis Treatment Scheme." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A381. doi: https://doi.org/10.1016/j.jval.2014.08.2621
Kulikov A, Komarov I, Zinchuk I. Pharmacoeconomic Analysis Tofacitinib Use in Rheumatoid Arthritis Treatment Scheme. Value Health. 2014 Nov;17(7):A381. doi: 10.1016/j.jval.2014.08.2621. Epub 2014 Oct 26. PMID: 27200847.
Copy Download .nbib Format: NLM
Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis.

Expert review of clinical pharmacology

Korman AM, Hill D, Alikhan A, Feldman SR.
PMID: 26881913
Expert Rev Clin Pharmacol. 2016;9(4):525-539. doi: 10.1586/17512433.2016.1154785. Epub 2016 Mar 07.

New treatments for psoriasis have been developed based on increasing knowledge of the underlying pathogenesis of the disease. The development of very safe and highly effective biologics has revolutionized the treatment of moderate-to-severe psoriasis. Biologics are not perfect, however,...

Cite
Korman AM, Hill D, Alikhan A, et al. Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis. Expert Rev Clin Pharmacol. 2016;9(4):525-539doi: 10.1586/17512433.2016.1154785.
Korman, A. M., Hill, D., Alikhan, A., & Feldman, S. R. (2016). Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis. Expert review of clinical pharmacology, 9(4), 525-539. https://doi.org/10.1586/17512433.2016.1154785
Korman, Abraham M, et al. "Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis." Expert review of clinical pharmacology vol. 9,4 (2016): 525-539. doi: https://doi.org/10.1586/17512433.2016.1154785
Korman AM, Hill D, Alikhan A, Feldman SR. Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis. Expert Rev Clin Pharmacol. 2016;9(4):525-539. doi: 10.1586/17512433.2016.1154785. Epub 2016 Mar 07. PMID: 26881913.
Copy Download .nbib Format: NLM
Tofacitinib citrate for ulcerative keratitis in a patient with rheumatoid arthritis.

Case reports in rheumatology

Meadow PB, Nguyen J, Kesavarapu K.
PMID: 25031879
Case Rep Rheumatol. 2014;2014:403452. doi: 10.1155/2014/403452. Epub 2014 Jun 17.

Purpose. To report a case of a patient with rheumatoid arthritis (RA) treated with tofacitinib citrate. Methods. Observational case report. Results. A 59-year-old patient, with a history of rheumatoid arthritis, on methotrexate 10 mg PO qwk and IV abatacept...

Cite
Meadow PB, Nguyen J, Kesavarapu K. Tofacitinib citrate for ulcerative keratitis in a patient with rheumatoid arthritis. Case Rep Rheumatol. 2014;2014:403452doi: 10.1155/2014/403452.
Meadow, P. B., Nguyen, J., & Kesavarapu, K. (2014). Tofacitinib citrate for ulcerative keratitis in a patient with rheumatoid arthritis. Case reports in rheumatology, 2014403452. https://doi.org/10.1155/2014/403452
Meadow, Philip B, et al. "Tofacitinib citrate for ulcerative keratitis in a patient with rheumatoid arthritis." Case reports in rheumatology vol. 2014 (2014): 403452. doi: https://doi.org/10.1155/2014/403452
Meadow PB, Nguyen J, Kesavarapu K. Tofacitinib citrate for ulcerative keratitis in a patient with rheumatoid arthritis. Case Rep Rheumatol. 2014;2014:403452. doi: 10.1155/2014/403452. Epub 2014 Jun 17. PMID: 25031879; PMCID: PMC4084676.
Copy Download .nbib Format: NLM
Higher Dose of Tofacitinib for Rheumatoid Arthritis Poses Risks.

JAMA

Voelker R.
PMID: 30938782
JAMA. 2019 Apr 02;321(13):1245. doi: 10.1001/jama.2019.2986.

No abstract available.

Cite
Voelker R. Higher Dose of Tofacitinib for Rheumatoid Arthritis Poses Risks. JAMA. 2019;321(13):1245doi: 10.1001/jama.2019.2986.
Voelker, R. (2019). Higher Dose of Tofacitinib for Rheumatoid Arthritis Poses Risks. JAMA, 321(13), 1245. https://doi.org/10.1001/jama.2019.2986
Voelker, Rebecca. "Higher Dose of Tofacitinib for Rheumatoid Arthritis Poses Risks." JAMA vol. 321,13 (2019): 1245. doi: https://doi.org/10.1001/jama.2019.2986
Voelker R. Higher Dose of Tofacitinib for Rheumatoid Arthritis Poses Risks. JAMA. 2019 Apr 02;321(13):1245. doi: 10.1001/jama.2019.2986. PMID: 30938782.
Copy Download .nbib Format: NLM
Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies.

Intestinal research

Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi I, Hibi T.
PMID: 30090051
Intest Res. 2018 Jul;16(3):499-501. doi: 10.5217/ir.2018.16.3.499. Epub 2018 Jul 27.

[This corrects the article on p. 233 in vol. 16, PMID: 29743836.].

Cite
Motoya S, Watanabe M, Kim HJ, et al. Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res. 2018;16(3):499-501doi: 10.5217/ir.2018.16.3.499.
Motoya, S., Watanabe, M., Kim, H. J., Kim, Y. H., Han, D. S., Yuasa, H., Tabira, J., Isogawa, N., Arai, S., Kawaguchi, I., & Hibi, T. (2018). Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intestinal research, 16(3), 499-501. https://doi.org/10.5217/ir.2018.16.3.499
Motoya, Satoshi, et al. "Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies." Intestinal research vol. 16,3 (2018): 499-501. doi: https://doi.org/10.5217/ir.2018.16.3.499
Motoya S, Watanabe M, Kim HJ, Kim YH, Han DS, Yuasa H, Tabira J, Isogawa N, Arai S, Kawaguchi I, Hibi T. Corrigendum: Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res. 2018 Jul;16(3):499-501. doi: 10.5217/ir.2018.16.3.499. Epub 2018 Jul 27. PMID: 30090051; PMCID: PMC6077317.
Copy Download .nbib Format: NLM
A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor.

JAAD case reports

Koike Y, Murayama N, Kuwatsuka Y, Utani A.
PMID: 29034299
JAAD Case Rep. 2017 Oct 06;3(6):498-500. doi: 10.1016/j.jdcr.2017.06.028. eCollection 2017 Nov.

No abstract available.

Cite
Koike Y, Murayama N, Kuwatsuka Y, et al. A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor. JAAD Case Rep. 2017;3(6):498-500doi: 10.1016/j.jdcr.2017.06.028.
Koike, Y., Murayama, N., Kuwatsuka, Y., & Utani, A. (2017). A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor. JAAD case reports, 3(6), 498-500. https://doi.org/10.1016/j.jdcr.2017.06.028
Koike, Yuta, et al. "A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor." JAAD case reports vol. 3,6 (2017): 498-500. doi: https://doi.org/10.1016/j.jdcr.2017.06.028
Koike Y, Murayama N, Kuwatsuka Y, Utani A. A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor. JAAD Case Rep. 2017 Oct 06;3(6):498-500. doi: 10.1016/j.jdcr.2017.06.028. eCollection 2017 Nov. PMID: 29034299; PMCID: PMC5635246.
Copy Download .nbib Format: NLM
Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis.

Annals of gastroenterology

Paschos P, Katsoula A, Giouleme O, Sarigianni M, Liakos A, Athanasiadou E, Bekiari E, Tsapas A.
PMID: 30174394
Ann Gastroenterol. 2018 Sep-Oct;31(5):572-582. doi: 10.20524/aog.2018.0276. Epub 2018 May 10.

BACKGROUND: The aim of the study was to assess the efficacy and safety of tofacitinib and its impact on quality of life in patients with moderate-to-severe ulcerative colitis.METHODS: We conducted a systematic review and meta-analysis of randomized controlled trials...

Cite
Paschos P, Katsoula A, Giouleme O, et al. Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Ann Gastroenterol. 2018;31(5):572-582doi: 10.20524/aog.2018.0276.
Paschos, P., Katsoula, A., Giouleme, O., Sarigianni, M., Liakos, A., Athanasiadou, E., Bekiari, E., & Tsapas, A. (2018). Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Annals of gastroenterology, 31(5), 572-582. https://doi.org/10.20524/aog.2018.0276
Paschos, Paschalis, et al. "Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis." Annals of gastroenterology vol. 31,5 (2018): 572-582. doi: https://doi.org/10.20524/aog.2018.0276
Paschos P, Katsoula A, Giouleme O, Sarigianni M, Liakos A, Athanasiadou E, Bekiari E, Tsapas A. Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Ann Gastroenterol. 2018 Sep-Oct;31(5):572-582. doi: 10.20524/aog.2018.0276. Epub 2018 May 10. PMID: 30174394; PMCID: PMC6102462.
Copy Download .nbib Format: NLM
Chemical JAK inhibitors for the treatment of rheumatoid arthritis.

Expert opinion on pharmacotherapy

Nakayamada S, Kubo S, Iwata S, Tanaka Y.
PMID: 27690665
Expert Opin Pharmacother. 2016 Nov;17(16):2215-2225. doi: 10.1080/14656566.2016.1241237. Epub 2016 Oct 08.

INTRODUCTION: Considerable advances in the treatment of rheumatoid arthritis (RA) have been made following the advent of biological disease-modifying anti-rheumatic drugs (DMARDs). However, biological DMARDs require intravenous or subcutaneous injection and some patients fail to respond to these drugs...

Cite
Nakayamada S, Kubo S, Iwata S, et al. Chemical JAK inhibitors for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2016;17(16):2215-2225doi: 10.1080/14656566.2016.1241237.
Nakayamada, S., Kubo, S., Iwata, S., & Tanaka, Y. (2016). Chemical JAK inhibitors for the treatment of rheumatoid arthritis. Expert opinion on pharmacotherapy, 17(16), 2215-2225. https://doi.org/10.1080/14656566.2016.1241237
Nakayamada, Shingo, et al. "Chemical JAK inhibitors for the treatment of rheumatoid arthritis." Expert opinion on pharmacotherapy vol. 17,16 (2016): 2215-2225. doi: https://doi.org/10.1080/14656566.2016.1241237
Nakayamada S, Kubo S, Iwata S, Tanaka Y. Chemical JAK inhibitors for the treatment of rheumatoid arthritis. Expert Opin Pharmacother. 2016 Nov;17(16):2215-2225. doi: 10.1080/14656566.2016.1241237. Epub 2016 Oct 08. PMID: 27690665.
Copy Download .nbib Format: NLM
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis.

RMD open

Fleischmann RM, Huizinga TW, Kavanaugh AF, Wilkinson B, Kwok K, DeMasi R, van Vollenhoven RF.
PMID: 27493790
RMD Open. 2016 Jul 26;2(2):e000262. doi: 10.1136/rmdopen-2016-000262. eCollection 2016.

INTRODUCTION: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib monotherapy was previously shown to inhibit structural damage, reduce clinical signs and symptoms of RA, and improve physical functioning over 24 months in...

Cite
Fleischmann RM, Huizinga TW, Kavanaugh AF, et al. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open. 2016;2(2):e000262doi: 10.1136/rmdopen-2016-000262.
Fleischmann, R. M., Huizinga, T. W., Kavanaugh, A. F., Wilkinson, B., Kwok, K., DeMasi, R., & van Vollenhoven, R. F. (2016). Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD open, 2(2), e000262. https://doi.org/10.1136/rmdopen-2016-000262
Fleischmann, Roy M, et al. "Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis." RMD open vol. 2,2 (2016): e000262. doi: https://doi.org/10.1136/rmdopen-2016-000262
Fleischmann RM, Huizinga TW, Kavanaugh AF, Wilkinson B, Kwok K, DeMasi R, van Vollenhoven RF. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open. 2016 Jul 26;2(2):e000262. doi: 10.1136/rmdopen-2016-000262. eCollection 2016. PMID: 27493790; PMCID: PMC4964179.
Copy Download .nbib Format: NLM
Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis.

Journal of clinical medicine research

Tanida S, Ozeki K, Mizoshita T, Kitagawa M, Ozeki T, Tanaka M, Nishie H, Shimura T, Kubota E, Kataoka H.
PMID: 32010420
J Clin Med Res. 2020 Jan;12(1):36-40. doi: 10.14740/jocmr4037. Epub 2020 Jan 06.

BACKGROUND: The use of monotherapy with intensive granulocyte and monocyte adsorptive apheresis (GMA) or a Janus kinase (JAK) inhibitor has been limited to patients with refractory ulcerative colitis (UC). The efficacy and safety of combination therapy with tofacitinib (TOF)...

Cite
Tanida S, Ozeki K, Mizoshita T, et al. Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis. J Clin Med Res. 2020;12(1):36-40doi: 10.14740/jocmr4037.
Tanida, S., Ozeki, K., Mizoshita, T., Kitagawa, M., Ozeki, T., Tanaka, M., Nishie, H., Shimura, T., Kubota, E., & Kataoka, H. (2020). Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis. Journal of clinical medicine research, 12(1), 36-40. https://doi.org/10.14740/jocmr4037
Tanida, Satoshi, et al. "Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis." Journal of clinical medicine research vol. 12,1 (2020): 36-40. doi: https://doi.org/10.14740/jocmr4037
Tanida S, Ozeki K, Mizoshita T, Kitagawa M, Ozeki T, Tanaka M, Nishie H, Shimura T, Kubota E, Kataoka H. Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis. J Clin Med Res. 2020 Jan;12(1):36-40. doi: 10.14740/jocmr4037. Epub 2020 Jan 06. PMID: 32010420; PMCID: PMC6968921.
Copy Download .nbib Format: NLM
Correction: Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation.

BMJ open gastroenterology

[No authors listed]
PMID: 32128231
BMJ Open Gastroenterol. 2020 Feb 20;7(1):e000302corr1. doi: 10.1136/bmjgast-2019-000302corr1. eCollection 2020.

[This corrects the article DOI: 10.1136/bmjgast-2019-000302.].

Cite
Correction: Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol. 2020;7(1):e000302corr1doi: 10.1136/bmjgast-2019-000302corr1.
(2020). Correction: Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ open gastroenterology, 7(1), e000302corr1. https://doi.org/10.1136/bmjgast-2019-000302corr1
"Correction: Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation." BMJ open gastroenterology vol. 7,1 (2020): e000302corr1. doi: https://doi.org/10.1136/bmjgast-2019-000302corr1
Correction: Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol. 2020 Feb 20;7(1):e000302corr1. doi: 10.1136/bmjgast-2019-000302corr1. eCollection 2020. PMID: 32128231; PMCID: PMC7039591.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 594 entries